Jagsonpal Pharmaceuticals has set the record date for its 5:2 stock split for today, January 8, 2025. The announcement was made on October 23, 2024.
On April 30, 2004, the company had announced a 2:1 stock split, which took effect on July 20, 2004. This means for every share held by an investor, they received 2 shares after the split adjustment, effectively doubling the number of shares in circulation while maintaining the total value for shareholders.
In the second quarter of fiscal year 2025, Jagsonpal Pharmaceuticals reported robust financial growth compared to Q2FY24. Revenues grew by 29.2%, reaching ₹74.7 Crores, up from ₹57.8 Crores in the same period last year.
Operating EBITDA increased significantly by 46.0%, rising to ₹18.4 Crores from ₹12.6 Crores, driven by enhanced operational efficiency. The EBITDA margin expanded by 280 basis points, reaching 24.6% in Q2FY25, compared to 21.8% in Q2FY24.
Net profit (PAT) also saw a strong rise of 52.0%, amounting to ₹11.4 Crores, compared to ₹7.5 Crores in Q2FY24, highlighting the company’s strong profitability during the quarter.
agsonpal Pharmaceuticals is an Indian healthcare company dedicated to providing affordable and high-quality medical solutions worldwide. The company’s mission is to establish a global brand originating from India.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 8, 2025, 8:55 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
